His point about the good preclinical work “Antigen Express” did developing a vaccine for SARS is also moot. They couldn’t get more funds for that via Anna. But they completed a lot of that early science and research which was utilized and built upon to create the Ii-Key-SARS-CoV-2 Vaccine. And we already see millions of dollars for licensing go to the company. That’s a big difference!
(3)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links